期刊
JOURNAL OF CONTROLLED RELEASE
卷 237, 期 -, 页码 14-22出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2016.06.043
关键词
Allergic asthma; DC-targeting; DEC-205; Adenoviral vectors; Immunotherapy; Mucosa
资金
- Mercator Research Centre Ruhr [St-2010-0004]
- German Research Foundation [RTG1949/1]
- Ruhr University Bochum [FoRUM F787R-2013]
Considering the rising incidence of allergic asthma, the symptomatic treatments that are currently applied in most cases are less than ideal. Specific immunotherapy is currently the only treatment that is able to change the course of the disease, but suffers from a long treatment duration. A gene based immunization that elicits the targeting of allergens towards dendritic cells in a steady-state environment might have the potential to amend these difficulties. Here we used a replication deficient adenovirus to induce the mucosal expression of OVA coupled to a single-chain antibody against DEC-205. A single intranasal vaccination was sufficient to mitigate an OVA-dependent asthmatic phenotype in a murine model. Invasive airway measurements demonstrated improved lung function after Ad-Dec-OVA treatment, which was in line with a marked reduction of goblet cell hyperplasia and lung eosinophilia. Furthermore OVA-specific IgE titers and production of type 2 cytokines were significantly reduced. Together, the here presented data demonstrate the feasibility of mucosal expression of DEC-targeted allergens as a treatment of allergic asthma. (C) 2016 The Authors. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据